Skip to main content
. 2018 Mar 14;31(2):e00077-17. doi: 10.1128/CMR.00077-17

FIG 13.

FIG 13

Examples of advanced hybrid antibiotics undergoing clinical trials: cadazolid (hybrid 17) and TNP-2092, also known as CBR-2092 (hybrid 18). Cadazolid was derived by fusing ciprofloxacin and tedizolid (with overlapping pharmacophores), while TNP-2092 comprises ciprofloxacin and rifampin-derived pharmacophores. These hybrids display limited antibacterial activity against Gram-negative bacilli.